FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

Clinical trial NCT05950334 · COMPLETED

Trial details

NCT number: NCT05950334
Sponsor: Fate Therapeutics
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsed/Refractory B-Cell Lymphoma

Start date: 2023-11-16
Primary completion: 2025-06-06
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.